NORTHWESTERN MEdicine posters and presentations
We are proud to participate in the 2026 ADA Scientific Sessions.
Our attending faculty will present new research and the latest findings during the conference.
Our attending faculty will present new research and the latest findings during the conference.
|
Session
|
Presenter
|
Time/Location
All times in CT |
Friday, June 5
|
Oral Presentations – Session #1: What's New with Insulin Delivery Systems? (With ADA Presidents' Select Abstract Presentation)
|
2:00 – 3:30 pm
La Nouvelle Orleans B (Level 2) |
|
Symposium - Novel Metabolic Drivers Underlying the Development of Obesity
|
3:45 – 5:15 pm
343 (Level 3) |
|
Symposium – Bridging the Gap: Real-Time Diabetes Technology, Organizational Readiness, and Policy Solutions to Advance Care
|
3:45 – 5:15 pm
217 (Level 2) |
|
Symposium – Personalizing Diabetes Care: Tailoring the Intervention to the Cardiovascular Risk
PCE, PREVENT, SCORE-Diabetes: Understanding the CVD Risk Prediction Tools in People with Diabetes |
3:45 – 4:05 pm
La Nouvelle Orleans C (Level 2) |
|
Debate – BMI on Trial: Should It Still Define Obesity
|
5:30 – 6:30 pm
La Nouvelle Orleans B (Level 2) |
Saturday, June 6
|
Corporate Symposium – Glucagon Pharmacology as a Metabolic Signal: From Mechanism to Meaningful Outcomes — A Lightning-Talk Series
|
6:30 – 7:45 am
Grand Ballroom AB‚ Hilton New Orleans Riverside |
|
Symposium – The ADA's Standards of Care in Diabetes: 2026 Updates
Management of Diabetes in Pregnancy |
9:00 – 9:15 am
La Nouvelle Orleans B (Level 2) |
|
Professional Interest Group – Discussion on Women's Interprofessional Network of the ADA (WIN ADA): The Adaptive Edge—How to Lead Through Change Panel Discussion
|
11:30 am – 12:30 pm
Hall E-3 (Level 1) |
|
General Poster Session
CGM Data Provides Weekly Insulin Efsitora Dose Guidance Equivalent to the Current Standard of FBG and Hypoglycemia Events for T2D Basal Experienced Adults: A Retrospective Analysis [Board No. 1953] |
12:30 – 1:30 pm
Poster Hall (Halls D – E) |
|
Oral Presentations – Session #1: What's New with CGM Systems?
|
1:30 – 3:00 pm
La Nouvelle Orleans C (Level 2) |
|
Product Theaters – The Connected Continuum: Reducing Clinician Burden Across Care Settings with EHR Integrated Diabetes Data
|
Juan C. Espinoza Salomon, MD (Invited Speaker)
|
3:00 – 3:45 pm
Product Theater 2 |
Sunday, June 7
|
Panel Discussion – GLP-1RA Across the Lifespan: Who, When, and at What Cost?
Health System/Payor Perspective |
8:00 – 8:15 am
220 (Level 2) |
|
Oral Presentations – Metabolic and Glycemic Profiles in Pregnancies Affected by Diabetes
Dynamic CGM Models to Predict GDM: A GO MOMs Analysis [Board No. 1232] |
8:15 – 8:30 am
Hall E-2 (Level 1) |
|
General Poster Session
When Health Care Is Disrupted: A “Canary in the Coal Mine” Signal for Diabetes Care [Board No. 1461] |
12:30 – 1:30 pm
Poster Hall (Halls D – E) |
|
General Poster Session
Semaglutide Reduces Asthma-Related Adverse Outcomes in Patients with Comorbid Asthma and Obesity: A Post Hoc Analysis of the SELECT Trial [Board No. 1723] |
12:30 – 1:30 pm
Poster Hall (Halls D – E) |
|
General Poster Session
Differential Fatty Acids in Human Milk from Individuals with Gestational Diabetes [Board No. 2140] |
12:30 – 1:30 pm
Poster Hall (Halls D – E) |
|
Ask the Expert – AI and Innovation for Clinical Health Care Delivery in DM
|
Amisha Wallia, MD, MS
(Chair) |
1:30 – 3:00 pm
Hall E-3 (Level 1) |
|
Ask the Expert – AI and Innovation for Clinical Health Care Delivery in DM
Large Language Models and Clinical Innovation |
1:30 – 1:45 pm
Hall E-3 (Level 1) |
|
Symposium – Immune Modulatory Strategies for Next-Generation Cell Therapies
Immunoengineering to Induce Islets Graft Tolerance |
Jacqueline Burke, PhD
|
1:50 – 2:10 pm
343 (Level 3) |
|
Panel Discussion – Early Pregnancy Diabetes Screening Reexamined: GO MOMs or Hold Tight?
Can Early Pregnancy OGTT and CGM Be Used to Predict GDM and Large-for-Gestational-Age Birthweight? Primary Results from the GO MOMs Study |
4:30 – 4:42 pm
217 (Level 2) |
|
Symposium – Where Heart, Kidney, and Metabolism Collide: Innovations in the Holistic Approach to Care
Advancing CVD Prevention in CKM |
5:10 – 5:30 pm
Great Hall B (Level 1) |
Monday, June 8
|
Panel Discussion – Diabetes Technology Use Across Life Situations
|
Grazia Aleppo, MD
(Chair) |
8:00 – 9:30 am
Hall E-3 (Level 1) |
|
Symposium – The ADA and Centers for Diabetes Translation Research Symposium: Driving Innovation in Diabetes Translation
|
Amisha Wallia, MD, MS (Chair)
|
8:00 – 9:30 am
220 (Level 2) |
|
Symposium – The ADA and Centers for Diabetes Translation Research Symposium: Driving Innovation in Diabetes Translation
CDTR Chicago: Diabetes Health and Child Education Research Collaborative in Chicago |
8:10 – 8:20 am
220 (Level 2) |
|
ePoster Theater - Healthcare Delivery: Expanding Beyond the Individual
|
Jelena Kravarusic, MD, PhD (Moderator)
|
11:30 am – 12:30 pm
ePoster Theater A (Halls B1-C) |
|
ePoster Theater – Diabetes in Pregnancy: Mechanisms, Management, and Metabolic Imprinting
Differential Fatty Acids in Human Milk from Individuals with Gestational Diabetes [Board No. 2140] |
12:10 – 12:20 pm
ePoster Theater B (Halls B1-C) |
|
General Poster Session
Telehealth vs. In-Person Versions of a Diabetes Distress–Reducing Intervention for Teens [Board No. 1591] |
12:30 – 1:30 pm
Poster Hall (Halls D-E) |
|
General Poster Session
Glycemia Risk Index to Characterize Pediatric Type 1 Diabetes Population [Board No. 2126] |
12:30 – 1:30 pm
Poster Hall (Halls D-E) |
NORTHWESTERN MEDICINE endocrinology
|
Northwestern Medicine Endocrinology is a national leader in research and clinical care of endocrine diseases. The research program is supported by more than $9 million in funding and encompasses a wide range of concentrations that intersect with multiple specialties. Clinical experts are world-renowned in the treatment of cancers and diseases of the pituitary, thyroid, parathyroid and adrenal glands, as well as diagnosis and treatment of diabetes, thyroid cancer, polycystic ovarian syndrome and osteoporosis.
|